{"entity":{"id":"nct07311694","kind":"trial","name":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","aka":[],"tldr":"A phase 3 trial testing HRS-4357 in prostate cancer, now recruiting.","summary":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer is a phase 3 interventional study registered as NCT07311694, led by Jiangsu HengRui Medicine, and recruiting on the registry. Official title: A Phase III, Randomised, Open-Label, Multicenter Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer. Planned enrolment is 370 participants (estimated). The study started in 2026-02-02 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07311694","url":"https://clinicaltrials.gov/study/NCT07311694"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["hrs-4357"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07311694","phase":"3","setting":"A Phase III, Randomized, Open-Label, Multicenter Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","sponsor":"Jiangsu HengRui Medicine","participation":[{"nct":"NCT07311694","source":"https://clinicaltrials.gov/study/NCT07311694","fetchedAt":"2026-10-07T16:55:39.854Z","studySha256":"d3298b34bdd5031c90efa2d84621948f0501e9007304ba60dd226a3be06cf0a3","overallStatus":"RECRUITING","lastUpdatePosted":"2026-02-04","leadSponsor":"Jiangsu HengRui Medicine Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":370,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-02-02","startedType":"actual","enrolled":370,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07311694/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"hrs-4357","kind":"drug","name":"HRS-4357","route":"/drugs/hrs-4357/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}